ABBV•benzinga•
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
Summary
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 17, 2024 by benzinga